Product Description: EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity[1].
Applications: Cancer-programmed cell death
Formula: C88H112N16O28S3
References: [1]Wang Z, et al. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Bioconjug Chem. 2018 Sep 19;29(9):3213-3221.
CAS Number: 2375590-67-1
Molecular Weight: 1938.12
Research Area: cancer
Target: PSMA;Radionuclide-Drug Conjugates (RDCs)
Deutsch
English
